SAGE THERAPEUTICS INC's ticker is SAGE and the CUSIP is 78667J108. A total of 247 filers reported holding SAGE THERAPEUTICS INC in Q4 2020. The put-call ratio across all filers is 1.22 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2022 | $626,000 | -21.0% | 18,925 | +1.6% | 0.00% | -25.0% |
Q4 2021 | $792,000 | -3.4% | 18,625 | +0.6% | 0.00% | -20.0% |
Q3 2021 | $820,000 | -19.3% | 18,505 | +3.5% | 0.01% | -16.7% |
Q2 2021 | $1,016,000 | -27.7% | 17,876 | -4.7% | 0.01% | -33.3% |
Q1 2021 | $1,405,000 | -13.7% | 18,766 | -0.3% | 0.01% | -18.2% |
Q4 2020 | $1,628,000 | +41.9% | 18,816 | +0.3% | 0.01% | +22.2% |
Q3 2020 | $1,147,000 | +46.9% | 18,766 | -0.1% | 0.01% | +50.0% |
Q2 2020 | $781,000 | -26.5% | 18,786 | -49.2% | 0.01% | -33.3% |
Q1 2020 | $1,062,000 | -47.6% | 36,995 | +31.9% | 0.01% | -47.1% |
Q4 2019 | $2,025,000 | -48.3% | 28,055 | +0.5% | 0.02% | -51.4% |
Q3 2019 | $3,918,000 | -40.3% | 27,925 | -22.1% | 0.04% | -12.5% |
Q2 2019 | $6,563,000 | +23.2% | 35,845 | +7.1% | 0.04% | +17.6% |
Q1 2019 | $5,325,000 | +76.0% | 33,478 | +6.0% | 0.03% | +54.5% |
Q4 2018 | $3,025,000 | -32.2% | 31,577 | -0.0% | 0.02% | -21.4% |
Q3 2018 | $4,462,000 | +179.4% | 31,587 | +209.7% | 0.03% | +64.7% |
Q2 2018 | $1,597,000 | – | 10,200 | – | 0.02% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
DAFNA Capital Management LLC | 99,306 | $14,027,000 | 5.76% |
Casdin Capital, LLC | 312,000 | $44,070,000 | 5.36% |
Palo Alto Investors LP | 840,372 | $118,703,000 | 4.80% |
BB BIOTECH AG | 1,071,373 | $151,331,000 | 4.00% |
TRV GP II, LLC | 37,362 | $5,277,000 | 3.10% |
Eversept Partners, LP | 43,621 | $6,161,466 | 2.70% |
RA Capital Management | 350,933 | $49,569,000 | 2.65% |
Eventide Asset Management | 494,000 | $69,778,000 | 2.56% |
OAK RIDGE INVESTMENTS LLC | 241,099 | $34,055,000 | 1.88% |
SUFFOLK CAPITAL MANAGEMENT LLC | 93,000 | $13,136,000 | 1.87% |